Results 21 to 30 of about 42,053 (249)

ISTH guidelines for treatment of thrombotic thrombocytopenic purpura

Journal of Thrombosis and Haemostasis, 2020
Despite advances in treatment options for thrombotic thrombocytopenic purpura (TTP), there are still limited high quality data to inform clinicians regarding its appropriate treatment.
X. L. Zheng, S. Vesely, S. Cataland, P. Coppo, B. Geldziler, A. Iorio, M. Matsumoto, R. Mustafa, M. Pai, G. Rock, L. Russell, R. Tarawneh, J. Valdes, F. Peyvandi   +13 more
semanticscholar   +1 more source

Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.

Blood Advances, 2020
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening condition. In 2018, the nanobody caplacizumab was approved for the treatment of adults experiencing an acute episode of aTTP, in conjunction with plasma exchange (PEX) and
L. Völker, J. Kaufeld, Wolfgang A. Miesbach, Sebastian Brähler, M. Reinhardt, Lucas Kühne, A. Mühlfeld, A. Schreiber, J. Gaedeke, M. Tölle, W. Jabs, Fedai Özcan, S. Markau, M. Girndt, F. Bauer, T. Westhoff, H. Felten, M. Hausberg, M. Brand, J. Gerth, M. Bieringer, M. Bommer, S. Zschiedrich, J. Schneider, S. Elitok, A. Gawlik, A. Gäckler, A. Kribben, V. Schwenger, U. Schoenermarck, M. Roeder, J. Radermacher, J. Bramstedt, A. Morgner, R. Herbst, Ana Harth, S. Potthoff, C. von Auer, R. Wendt, H. Christ, P. Brinkkoetter, J. Menne   +41 more
semanticscholar   +1 more source

Acquired thrombotic thrombocytopenic purpura with possible association with AstraZeneca‐Oxford COVID‐19 vaccine

eJHaem, 2021
Acquired thrombotic thrombocytopenic purpura is characterized by the microvascular aggregation of platelets and microangiopathic hemolytic anemia causing ischemia of multiple organs including the brain mainly and less likely the kidney and the heart. The
M. Al‐Ahmad, M. Al-Rasheed, Neveen A. Shalaby   +2 more
semanticscholar   +1 more source

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

New England Journal of Medicine, 2019
BACKGROUND In acquired thrombotic thrombocytopenic purpura (TTP), an immune‐mediated deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis ...
M. Scully, S. Cataland, F. Peyvandi, P. Coppo, P. Knöbl, J. Hovinga, A. Metjian, J. de la Rubia, K. Pavenski, F. Callewaert, Debjit Biswas, H. de Winter, R. Zeldin   +12 more
semanticscholar   +1 more source

Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine

Journal of Thrombosis and Haemostasis, 2021
In December 2020 the Israeli Health Ministry began a mass vaccination campaign with the BNT162b2 vaccine. This was an important step in overcoming the severe acute respiratory syndrome corona virus 2 (SARS‐CoV‐2) pandemic. Autoimmune phenomenon have been
H. Maayan, I. Kirgner, O. Gutwein, K. Herzog-Tzarfati, N. Rahimi-Levene, M. Koren-Michowitz, D. Blickstein   +6 more
semanticscholar   +1 more source

Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura [PDF]

Nature, 2001
Gallia G. Levy, William C. Nichols, Eric C.‐Y. Lian, Tatiana Foroud, Jeanette N. McClintick, Beth McGee, Angela Yang, David Siemieniak, Kenneth R. Stark, Ralph A. Gruppo, Ravi Sarode, Susan B. Shurin, Visalam Chandrasekaran, Sally P. Stabler, Hernan Sabio, Eric E. Bouhassira, Jefferson D. Upshaw, David Ginsburg, Han‐Mou Tsai   +18 more
openalex   +2 more sources

Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single-Institution Experience

Balkan Medical Journal, 2018
Background: Thrombotic thrombocytopenic purpura is a potentially life-threatening condition. Although the introduction of therapeutic plasma exchange has reduced mortality rates from over 90% to 10%-20%, approximately 40% of patients relapse, and ...
Seniz Öngören, Ayşe Salihoğlu, Tuğçe Apaydın, Sevil Sadri, Ahmet Emre Eşkazan, Muhlis Cem Ar, Tuğrul Elverdi, Zafer Başlar, Yıldız Aydın, Teoman Soysal   +9 more
doaj   +1 more source

Treatment of thrombotic thrombocytopenic purpura

Terapevticheskii arkhiv, 2021
The review discusses approaches to treatment of congenital thrombotic thrombocytopenic purpura (TTP) or Upshaw-Schulman syndrome. In congenital TTP, plasma transfusions are sufficient. Such treatment options as plasma exchange, administration of clotting factor VIII concentrate, recombinant ADAMTS13, are also used.
Gennadii M. Galstyan, Alexei A. Maschan, Elizaveta E. Klebanova, Irina I. Kalinina   +3 more
openaire   +7 more sources

Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura

Haematologica, 2016
Acquired thrombotic thrombocytopenic purpura is primarily caused by the deficiency of plasma ADAMTS13 activity resulting from autoantibodies against ADAMTS13.
Wenjing Cao, Huy P. Pham, Lance A. Williams, Jenny McDaniel, Rance C. Siniard, Robin G. Lorenz, Marisa B. Marques, X. Long Zheng   +7 more
doaj   +1 more source

Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.

Blood, 2020
Acquired thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease characterized by thrombotic microangiopathy leading to end-organ damage. The standard of care (SOC) treatment is therapeutic plasma exchange (TPE) alongside immunomodulation
George Goshua, P. Sinha, J. Hendrickson, C. Tormey, Pavan K Bendapudi, A. Lee   +5 more
semanticscholar   +1 more source